Oncoinvent ASA: Second half 2025 results
Oslo, Norway, 26 February 2026: Oncoinvent (OSE: ONCIN), a biotech company developing a receptor-independent alpha radiopharmaceutical to eradicate cancer cells in the abdominal cavity after surgery with a single, targeted dose, today announces its second half 2025 results.
Oncoinvent's management team will give an online presentation to investors, analysts and the press at 09:30 CET today (details below).
Highlights:
Radspherin[®]
· Reported positive final data from Phase 1 Trial of Radspherin[®] to treat ovarian cancer · Published Phase 1 trial results for Radspherin[®] in ovarian cancer in Gynecologic Oncology · Presented final safety and efficacy results from the Phase 1/2a trial of Radspherin[®] to treat colorectal cancer at the 15th PSOGI International Congress on Peritoneal Surface Malignancies
Corporate
· Completed merger with BerGenBio and successfully uplisted to Oslo Stock Exchange · Raised NOK 130 million in equity · Appointed Dr Ramzi Amri as Chief Financial Officer
Post-period highlights
· January 2026: Included four additional sites in Oncoinvent's Phase 2 trial · February 2026: Present positive 24-month follow-up data from Phase 1 ovarian cancer trial of Radspherin[®] at 27th Congress of the European Society of Gynecological Oncology (ESGO) 2026
Oystein Soug, CEO, commented: "The second half of 2025 marked another productive period for Oncoinvent, with solid advances across our clinical programs together with important corporate and financial milestones. During the period, we progressed the Radspherin[®] Phase 2 trial in ovarian cancer, delivered meaningful scientific updates in two cancer indications, completed significant strategic transactions, and in the process strengthened the company's financial foundation ahead of the planned Phase 2 interim readout."
Presentation:
We invite to a live webcast today at 09.30 CET. It will be possible to submit questions during the presentation.
· Date: Thursday, 26 February 2026 · Time: 9:30am CET · Webcast link: https://qcnl.tv/p/l-V8RQZomSSettvFIGnxjg
A recording of the webcast will be made available on www.oncoinvent.com after the live sending.
Reporting material:
· Oncoinvent 2H 2025 report (https://mb.cision.com/Public/15728/4313178/b79ae34c93871998.pdf) · Oncoinvent 2H25 presentation (https://mb.cision.com/Public/15728/4313178/b034e378391f908e.pdf)
The reporting material are also available in the Investor Relations section of the Company's website at www.oncoinvent.com.
***
For further information, please contact:
Oystein Soug, Chief Executive Officer Email: IR@oncoinvent.com (soug@oncoinvent.com)
This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act. This stock exchange announcement was published by Renate Birkeli, Director Investor Relations, on behalf of the Company, at the time and date stated above in this announcement.
About Oncoinvent
Oncoinvent is developing Radspherin®, a receptor-independent alpha radiation therapy that leverages the unique anatomy of the abdominal cavity to destroy residual micrometastases using a single, highly localized dose of alpha radiation. The initial clinical focus is treatment of ovarian and colorectal cancer patients after surgical removal of the primary tumor and visible metastases in the peritoneum, the thin membrane lining the abdominal cavity and covering the abdominal organs.
This radiopharmaceutical is designed to prevent or delay recurrence in the peritoneal cavity, keeping patients disease-free for longer than the current standard of care and thereby also impacting overall survival. It is broadly applicable to any cancer that spreads to the peritoneum, e.g. ovarian, colorectal, and gastric cancers. Radspherin stands out for its simplicity, excellent safety profile, and seamless integration into existing surgical workflows. Oncoinvent's product is easy to use, avoids systemic delivery and significant toxicity. It is also differentiated in being simple to manufacture, scalable, and supply de-risked.
Data from two trials in ovarian (phase 1) and colorectal (phase 1/2a) cancers, are highly promising, showing an excellent safety profile and meaningful signals of efficacy. Interim data from an ongoing, randomized, controlled phase 2 ovarian cancer trial is expected in 2026. With cost-effective manufacturing, blockbuster potential, active pharma partnership momentum, plus strong endorsements from leading experts, Oncoinvent is built for scale and commercial success, and is set to become the new standard for post-surgical cancer care. The Company was founded by the originators of Algeta and Xofigo (acquired by Bayer).